Supraja R Prasad | Drug Discovery and Development | Best Researcher Award

Published on 11/11/2025 by Top Pharmaceutical

Ms. Supraja R Prasad | Drug Discovery and Development | Best Researcher Award

Kuvempu University | India

Ms. Supraja R. Prasad is a passionate researcher and educator specializing in organic synthesis, computational chemistry, and the design of biologically active heterocycles. Her academic and professional journey reflects a deep dedication to the integration of sustainable chemical methodologies with modern computational tools to advance the field of drug discovery. She is particularly recognized for her innovative work on the green synthesis of heterocyclic compounds, utilizing eco-friendly multicomponent reactions and natural catalysts to create molecular frameworks with promising therapeutic potential.Her research portfolio spans multiple interrelated areas, including mechanochemical synthesis of heterocyclic derivatives, density functional theory (DFT) studies, and spectral characterization of synthesized compounds. She has also explored the anti-diabetic activity of synthesized derivatives, focusing on developing safer and more efficient alpha-glucosidase inhibitors for managing type 2 diabetes mellitus. By combining experimental synthesis with computational modeling and molecular docking analyses, Ms. Prasad bridges the gap between theoretical chemistry and practical pharmacological applications.Her recent publication in the Journal of the Indian Chemical Society highlights her contributions to the synthesis and evaluation of alpha-glucosidase inhibitors, further strengthening her position within the scientific community. Through her work, she demonstrates how green chemistry can drive meaningful advancements in pharmaceutical sciences while minimizing environmental impact.Ms. Prasad’s academic mission is rooted in the belief that collaborative, interdisciplinary research can accelerate innovation. She emphasizes teamwork, creativity, and knowledge sharing as the cornerstones of impactful scientific progress. Her approach integrates sustainability, molecular insight, and therapeutic relevance — a combination that continues to shape her vision for future research.Her ongoing studies and contributions to organic synthesis, bioactivity assessment, and computational modeling position her as an emerging leader in sustainable chemistry and computational drug discovery, striving to make scientific research both environmentally responsible and socially beneficial.

Profile: Orcid

Featured Publications

Clay catalyzed dihydropyrimidinone synthesis: α-glucosidase inhibition and chemoinformatics. Journal of the Indian Chemical Society.

Zaneta Nikolovska-Coleska | Drug Discovery and Development | Best Researcher Award

Published on 04/11/2025 by Top Pharmaceutical

Prof. Dr. Zaneta Nikolovska-Coleska | Drug Discovery and Development | Best Researcher Award

University of Michigan Medical School Department of Pathology | United States

Prof. Dr. Zaneta Nikolovska-Coleska is an accomplished pharmaceutical chemist and molecular pharmacologist recognized for her groundbreaking work in the design, synthesis, and development of molecularly targeted small molecules for cancer treatment. She earned her foundational and advanced degrees in pharmaceutical chemistry from the Faculty of Pharmacy at the University Ss. Cyril and Methodius in Skopje, where she also began her academic career as a young assistant and later advanced through multiple teaching and research positions. Her dedication to chemical sciences and biomedical innovation led her to the University of Michigan, Ann Arbor, where she currently serves as a Professor in the Department of Pathology and Associate Dean for Graduate and Postdoctoral Studies.Dr. Nikolovska-Coleska’s research is centered on the discovery of small molecule inhibitors that target protein–protein interactions involved in apoptosis, oncogenic signaling pathways, and epigenetic regulation. Her laboratory investigates mechanisms such as Mcl-1–Bim/Noxa, Bfl-1–Bim/Noxa, EZH2–p38 MAP kinase interactions, and histone methyltransferase activities, contributing to the identification of novel therapeutic targets for various malignancies. Through her integrative approach, combining chemical biology, medicinal chemistry, and translational oncology, she has developed promising compounds for the modulation of signaling pathways implicated in cancer progression and resistance.Her clinical and translational research extends into precision medicine, where she applies functional assays to predict anti-cancer drug responses, aiming to enhance individualized therapeutic strategies. As a clinician-research scholar and educator, she has mentored numerous postdoctoral fellows, clinical trainees, and graduate students, guiding them in developing innovative research methodologies and critical scientific reasoning.Throughout her illustrious career, Dr. Nikolovska-Coleska has played pivotal roles in multiple large-scale research initiatives, serving as Principal Investigator, Co-Investigator, and Mentor on numerous national and international grants focused on cancer biology, aging, and drug discovery. Her collaborations with global scientific institutions and pharmaceutical organizations have contributed to the advancement of targeted therapies, including the development of inhibitors against oncogenic proteins such as DOT1L, Mcl-1, EZH2, and PAPP-A.In addition to her research excellence, Dr. Nikolovska-Coleska has made outstanding contributions to academic leadership. As Director of the Molecular and Cellular Pathology Graduate Program and Associate Director of Academic Programs in Biomedical Sciences, she has overseen curriculum development, student recruitment, academic policy, and interdisciplinary research training. Her vision continues to shape the next generation of biomedical scientists, emphasizing the integration of molecular insights with clinical applications.Through her scholarly achievements, mentorship, and leadership, Prof. Dr. Zaneta Nikolovska-Coleska stands as a leading figure in pharmaceutical chemistry and translational oncology, dedicated to advancing science that bridges molecular discovery with therapeutic innovation.

Profile: Google Scholar

Featured Publications

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., et al. (2006). Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2−p53 interaction. Journal of Medicinal Chemistry, 49(12), 3432–3435.

Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., et al. (2008). Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proceedings of the National Academy of Sciences, 105(10), 3933–3938.

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., et al. (2005). Structure-based design of potent non-peptide MDM2 inhibitors. Journal of the American Chemical Society, 127(29), 10130–10131.

Nikolovska-Coleska, Z., Wang, R., Fang, X., Pan, H., Tomita, Y., Li, P., Roller, P. P., et al. (2004). Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Analytical Biochemistry, 332(2), 261–273.

Nikolovska-Coleska, Z., Xu, L., Hu, Z., Tomita, Y., Li, P., Roller, P. P., Wang, R., et al. (2004). Discovery of embelin as a cell-permeable, small-molecular-weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine. Journal of Medicinal Chemistry, 47(10), 2430–2440.

Bagherian, M., Sabeti, E., Wang, K., Sartor, M. A., Nikolovska-Coleska, Z., et al. (2021). Machine learning approaches and databases for prediction of drug–target interaction: A survey paper. Briefings in Bioinformatics, 22(1), 247–269.

Wang, G., Nikolovska-Coleska, Z., Yang, C. Y., Wang, R., Tang, G., Guo, J., et al. (2006). Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. Journal of Medicinal Chemistry, 49(21), 6139–6142.

Xiangxuan Zhao | Drug Discovery and Development | Best Researcher Award

Published on 23/09/2025 by Top Pharmaceutical

Prof. Xiangxuan Zhao | Drug Discovery and Development | Best Researcher Award

Liaoning University of Traditional Chinese Medicine | China

Prof. Xiangxuan Zhao is a distinguished cell biologist and an eminent academic leader renowned for his pioneering contributions to the field of natural medicine-derived anti-cancer therapeutics. Serving as Professor, Doctoral Supervisor, and Postdoctoral Mentor, he holds prestigious positions as the Dean of the College of Laboratory Animal Medicine and Director of the Laboratory Animal Center at the Liaoning University of Traditional Chinese Medicine in Shenyang, China. With a career dedicated to advancing the frontiers of cancer biology and pharmaceutical innovation, Prof. Zhao has established himself as a leading authority in tumor drug resistance mechanisms, molecular target discovery, molecular targeted drug development, and tumor immunotherapy research.Prof. Zhao’s academic journey reflects a blend of scientific rigor and innovative leadership. Prior to his current roles, he contributed significantly as Deputy Director of the Engineering Technology Center for TCM Innovation at Liaoning University of Traditional Chinese Medicine and as a Researcher at the Health Science Research Institute of China Medical University. His earlier tenure as an Associate Researcher at Shengjing Hospital, China Medical University, laid the groundwork for his expertise in translational medicine, fostering a seamless bridge between laboratory research and clinical applications.A prolific scholar, Prof. Zhao has authored and co-authored eighty-four academic papers, including thirty-one SCI-indexed publications with a cumulative impact factor of one hundred eighty-eight. Among these, five papers boast impact factors exceeding ten, with his highest-impact publication reaching an impressive twenty-seven point four. His scientific excellence is further reflected in the thirteen national patents he holds, with four as the first inventor, underscoring his role as a trailblazer in molecular oncology and therapeutic innovation.

Profile: Orcid

Featured Publications

Liu, Y., Guo, R., Xue, C., Zhang, X., Xiao, F., Zhao, X., Zhu, Z., & Li, K. (2025). Phytosphingosine suppresses gastric cancer through SFRP4/β-catenin axis-mediated Wnt signaling pathway inhibition. Chemico-Biological Interactions.

Ke, W., Wang, H., Zhao, X., & Lu, Z. (2021). Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma. Food & Function.

Sun, W., Ren, Y., Lu, Z., & Zhao, X. (2020). The potential roles of exosomes in pancreatic cancer initiation and metastasis. Molecular Cancer.

Ke, W., Zhao, X., & Lu, Z. (2020). Bcl-2 is essential for Foeniculum vulgare seed extract-induced apoptosis in lung cancer. Research Square.

Basharat Ali | Drug Discovery and Development | Best Researcher Award

Published on 19/09/202520/09/2025 by Top Pharmaceutical

Assist. Prof. Dr. Basharat Ali | Drug Discovery and Development | Pakistan

University of Baltistan | Pakistan

Assist. Prof. Dr. Basharat Ali is a distinguished researcher and academician specializing in medicinal chemistry, heterocyclic synthesis, and polymer science with extensive expertise in designing and synthesizing biologically active compounds. Currently serving as an Assistant Professor in the Department of Chemistry at the University of Baltistan, Skardu, Pakistan, he has a diverse academic and research background, including postdoctoral research at the College of Pharmaceutical Science, Soochow University, China, where he contributed to the development of chemiluminescent dioxetane probes for disease diagnosis, fluorescent probes for hydrogen sulfide detection, and anthraquinone derivatives as anti-infective agents. He has also worked as a research assistant at Zhejiang University, China, focusing on mechanistic studies of olefin polymerization using α-Diimine nickel(II) catalysts, and at the HEJ Research Institute of Chemistry, University of Karachi, where he specialized in synthetic organic chemistry and bioactive heterocycles.Dr. Basharat Ali’s research interests include the synthesis, structural modification, and biological evaluation of medicinally important synthetic derivatives, probe design for environmental and biomedical applications, multicomponent reactions, polymer synthesis, and catalytic system development. He has supervised numerous postgraduate students and contributed extensively to the field with multiple high-impact publications in reputable international journals. Some of his significant research publications include Synthesis and biological evaluations of 1,3,4-thiadiazole derivatives as dual acting enzyme inhibitors to target inflammation and diabetes, Carbothioamides as anticancer agents: synthesis, in-vitro activity, structure-activity relationship evaluations and molecular docking, Synthesis of (E)-3-(aryl)-1-phenylprop-2-en-1-one Chalcone Derivatives for Hyperglycemic Effect in Diabetes.

Profile: Google Scholar

Featured Publications

Li, S., Zhan, L., Zhao, W., Zhang, S., Ali, B., Fu, Z., Lau, T. K., Lu, X., Shi, M., Li, C. Z., … (2018). Revealing the effects of molecular packing on the performances of polymer solar cells based on A–D–C–D–A type non-fullerene acceptors. Journal of Materials Chemistry A, 6(25), 12132–12141.

Ali, F., Khan, K. M., Salar, U., Iqbal, S., Taha, M., Ismail, N. H., Perveen, S., … (2016). Dihydropyrimidones: As novel class of β-glucuronidase inhibitors. Bioorganic & Medicinal Chemistry, 24(16), 3624–3635.

Abbas, A., Ali, B., Khan, K. M., Iqbal, J., Rahman, S. U., Zaib, S., Perveen, S. (2019). Synthesis and in vitro urease inhibitory activity of benzohydrazide derivatives, in silico and kinetic studies. Bioorganic Chemistry, 82, 163–177.

Ali, B., Khan, K. M., Hussain, S., Hussain, S., Ashraf, M., Riaz, M., Wadood, A., … (2018). Synthetic nicotinic/isonicotinic thiosemicarbazides: In vitro urease inhibitory activities and molecular docking studies. Bioorganic Chemistry, 79, 34–45.

Naz, F., Latif, M., Salar, U., Khan, K. M., Al-Rashida, M., Ali, I., Ali, B., Taha, M., … (2020). 4-Oxycoumarinyl linked acetohydrazide Schiff bases as potent urease inhibitors. Bioorganic Chemistry, 105, 104365.

Salar, U., Khan, K. M., Taha, M., Ismail, N. H., Ali, B., Perveen, S., Ghufran, M., … (2017). Biology-oriented drug synthesis (BIODS): In vitro β-glucuronidase inhibitory and in silico studies on 2-(2-methyl-5-nitro-1H-imidazol-1-yl) ethyl aryl carboxylate derivatives. European Journal of Medicinal Chemistry, 125, 1289–1299.

Ali, M., Khan, K. M., Salar, U., Ashraf, M., Taha, M., Wadood, A., Hamid, S., Riaz, M., … (2018). Synthesis, in vitro α-glucosidase inhibitory activity, and in silico study of (E)-thiosemicarbazones and (E)-2-(2-(arylmethylene)hydrazinyl)-4-arylthiazole derivatives. Molecular Diversity, 22(4), 841–861.

Wuting Lu | Drug Discovery and Development | Best Researcher Award

Published on 10/09/202510/09/2025 by Top Pharmaceutical

Dr. Wuting Lu | Drug Discovery and Development | Best Researcher Award

Dr. Wuting Lu at Jiangxi Academy of Sciences | China

Dr. Wuting Lu is a dedicated researcher specializing in immunotoxicology, neurobiology, and aquatic toxicology. With a strong academic background and diverse research experience, Dr. Lu has contributed significantly to understanding environmental toxicants and their effects on immunity and neurodevelopment using zebrafish models. He has participated in multiple National Natural Science Foundation of China projects, focusing on mechanisms of high-risk autism genes and their impact on the gut-immune-brain axis. His work has resulted in several high-impact journal publications, advancing knowledge in environmental safety, immunology, and neurobiology. Currently, he serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences.

Publication Profile

Orcid

Education

Dr. Wuting Lu completed his Ph.D. in Biology at Nanchang University, where his research explored immunotoxicity and neurodevelopmental effects of environmental pollutants. He earned his M.S. in Neurobiology, also from Nanchang University, focusing on molecular and cellular mechanisms in the nervous system. His academic journey began with a B.S. in Aquaculture at Dalian Ocean University, providing him with a strong foundation in aquatic biology and toxicology. This multidisciplinary training enabled him to integrate environmental science, immunology, and neuroscience into his research, developing expertise in both experimental techniques and advanced molecular analysis approaches for investigating complex biological interactions.

Experience

Dr. Wuting Lu professional career includes roles in academic research and laboratory management. He currently serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences, where he investigates immunotoxicity and neurotoxicity mechanisms. Before this, he worked as a Laboratory Technician at Jinggangshan University, gaining hands-on experience in molecular biology, immunology, and laboratory safety management. He has actively participated in several National Natural Science Foundation of China projects, contributing to studies on autism gene regulation, microglial activation, and the gut-immune-brain axis. His multidisciplinary experience spans aquatic toxicology, neurobiology, immunology, and transcriptomic analysis, bridging fundamental research with environmental health concerns.

Awards and Honors

Dr. Wuting Lu has received recognition for his research contributions through participation in multiple National Natural Science Foundation of China projects, including studies on the high-risk autism gene CHD8 and its effects on microglial activation and the gut-immune-brain axis. His publications in leading journals, such as Fish & Shellfish Immunology and Ecotoxicology and Environmental Safety, highlight his impactful work on immunotoxicity, neurotoxicity, and antioxidant mechanisms in aquatic organisms. While early in his independent research career, his achievements demonstrate excellence in experimental design, molecular analysis, and scientific communication, positioning him as a promising researcher in environmental health and neuroimmunology fields.

Research Focus

Dr. Wuting Lu research focuses on immunotoxicity, neurotoxicity, and environmental safety, particularly investigating the effects of environmental toxicants on immune and nervous system development using zebrafish as a model organism. He explores molecular mechanisms underlying pollutant-induced oxidative stress, immune dysregulation, and neurodevelopmental impairments. Additionally, he studies the regulatory roles of genes, such as CHD8, in microglial activation and the gut-immune-brain axis, linking environmental exposures to autism spectrum disorders. His work integrates toxicology, transcriptomics, and neuroimmunology to elucidate pathways of toxicity, identify potential biomarkers, and provide insights into environmental risk assessment, contributing to public health and ecological sustainability research.

Publication Top Notes

Immunotoxicity and neurotoxicity induced by natural borneol and synthetic borneol in zebrafish (Danio rerio)

Immunotoxicity and transcriptome analysis of zebrafish embryos exposure to Nitazoxanide

Conclusion

Overall, Dr. Wuting Lu exhibits a strong research trajectory with impactful publications, interdisciplinary expertise, and contributions to nationally funded projects. His work in environmental toxicology, neurobiology, and molecular mechanisms aligns well with the objectives of the Best Researcher Award. With continued focus on independent project leadership and global collaboration, Dr. Lu has the potential not only to be a strong award candidate but also to emerge as a leading researcher in his field.

Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Published on 31/07/202504/08/2025 by Top Pharmaceutical

Prof. Dr. Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Director at nd Xiangya Hospital | Central South University | China

Prof. Dr. Dongshan Zhang is a highly respected Chief Physician and Professor at Central South University, China. A postdoctoral fellow trained in the United States, he is a PhD supervisor and a recipient of China’s National Top Talent Program for Science and Technology Leaders. As Director of both the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair, he leads cutting-edge medical research. With over 46 SCI publications and multiple patents, his work in acute kidney injury has earned him prestigious awards and international acclaim.

Publication Profile

Scopus

Education

Prof. Zhang pursued rigorous academic training in China and completed his postdoctoral fellowship in the United States, gaining advanced insights into nephrology and translational medicine. He earned his medical and doctoral degrees from top Chinese medical universities, where he laid the foundation for his expertise in acute organ injury. His exposure to international research environments shaped his multidisciplinary approach. Now, as a PhD supervisor, he mentors future scientists and clinicians, promoting global research collaborations and innovation in clinical nephrology and emergency medicine.

Experience

Prof. Zhang currently serves as Chief Physician and Professor at Central South University, where he is also a Distinguished Shenghua Scholar Professor. He directs two major research institutes: the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair in Hunan Province. Over his career, he has led four NSFC-funded national research projects and served as Associate Editor for top journals. His commercialized patents and extensive publication record reflect his commitment to translational research and clinical excellence.

Awards

Prof. Zhang’s outstanding contributions have earned him the First Prize of the Natural Science Award of Hunan Province. He has been recognized as a National Top Talent in Science and Technology, awarded for his pioneering work in nephrology and acute organ injury. His research papers have graced the covers of leading journals, affirming his global impact. As a Distinguished Shenghua Scholar Professor and active editorial board member, he continues to shape scientific thought and innovation. His accolades highlight both clinical expertise and trailblazing research excellence.

Research Focus

Prof. Zhang’s primary research centers on Acute Kidney Injury (AKI), encompassing mechanisms of injury, repair, and translational approaches to therapy. His work explores inflammation, apoptosis, and molecular pathways involved in kidney damage. He leads interdisciplinary teams to develop innovative drug targets and biomarkers, bridging basic science and clinical application. With support from multiple NSFC grants, his lab integrates in vivo models, molecular profiling, and AI-driven analytics to advance precision nephrology. His research contributes to improving prognosis and treatment in critical care settings.

Publication Top Notes

Title: PRDM16 acts as a homeostasis regulation factor to suppress the transition of AKI to CKD via upregulation of eukaryotic initiation factor 6
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: PRDM16 suppresses pyroptosis to attenuate the progression of AKI caused by rhabdomyolysis via upregulation of USP10
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: Mmu_circ_0005698/hsa_circ_0085381/miR-532-3p/Arhgdib axis mediates the ischemic progression of acute kidney injury
Journal: International Immunopharmacology
Year: 2025

Title: Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial
Journal: Nature Medicine
Year: 2025

Title: Inhibition of Mettl3 alleviates low-dose cisplatin-induced renal fibrosis and enhances the chemotherapeutic efficacy in mouse models of cancer
Journal: International Journal of Biological Sciences
Year: 2025

Title: PRDM16 suppresses ferroptosis to protect against sepsis-associated acute kidney injury by targeting the NRF2/GPX4 axis
Journal: Redox Biology
Year: 2024

Title: NRF1-induced mmu_circ_0001388/hsa_circ_0029470 confers ferroptosis resistance in ischemic acute kidney injury via the miR-193b-3p/TCF4/GPX4 axis
Journal: Life Sciences
Year: 2024

Title: Discovery and verification of mmu_Circ_26986/hsa_Circ_0072463 as a potential biomarker and intervention target for sepsis-associated acute kidney injury
Journal: Not specified
Year: Not specified

Conclusion

Prof. Dr. Dongshan Zhang is an outstanding candidate for the Research for Best Researcher Award, possessing an exceptional track record in acute organ injury research, prolific publication output, successful grant leadership, and tangible innovations through patents. His blend of academic excellence, clinical relevance, and translational success makes him a model researcher with substantial contributions to global health and kidney disease research. With minor expansion in global collaborations and strategic outreach, his impact can become even more internationally transformative.

Saikat Chaudhuri | Drug Discovery and Development | Best Researcher Award

Published on 08/07/202508/07/2025 by Top Pharmaceutical

Saikat Chaudhuri | Drug Discovery and Development | Best Researcher Award

Assist. Prof. Dr. Saikat Chaudhuri at CSIR-Central Leather Research Institute, India.

Assist. Prof. Dr. Saikat Chaudhuri is an accomplished organic chemist specializing in natural product synthesis and green chemistry. 🎓 He earned his Ph.D. from IISER Bhopal, focusing on Clavine alkaloids, and holds degrees from Visva Bharati and Burdwan Universities. 🏅 He is a recipient of the Young Scientist Award (2024) and prestigious UGC fellowships. At CSIR-CLRI, he teaches and mentors students across disciplines, guiding numerous projects and theses. 📚 His innovative research, backed by major grants, has led to impactful publications in synthesis and catalysis. 🧪 His work fuels advancements in affordable pharmaceutical chemistry and sustainable methodologies.

Publication Profile

Orcid

Education

Assist. Prof. Dr. Saikat Chaudhuri holds an impressive academic background in organic chemistry. He completed his Ph.D. in Organic Chemistry from IISER Bhopal (2013–2017) under the mentorship of Prof. Alakesh Bisai, focusing on the total syntheses of naturally occurring Clavine alkaloids 🧪. Prior to this, he earned his M.Sc. in Organic Chemistry from Visva Bharati University (2010–2012) 📘 and a B.Sc. (Hons.) in Chemistry from Burdwan University (2007–2010) 🔬. His strong academic foundation laid the groundwork for his research excellence and innovative contributions to synthetic organic chemistry and drug development.

Awards

Assist. Prof. Dr. Saikat Chaudhuri has been recognized with several prestigious honors throughout his academic journey. In 2024, he received the Young Scientist Award from the CRS Society, Vidyasagar University 🌟. Earlier, he was awarded the esteemed Dr. D.S. Kothari Postdoctoral Fellowship (2019–2021) by UGC, Government of India 🧪. During his doctoral research, he was a recipient of both Junior Research Fellowship (JRF) and Senior Research Fellowship (SRF) from UGC-NET (2013–2017) 📚. His early promise was evident when he earned the Swami Vivekananda Merit-cum-Means Scholarship (2011–2012) from the Govt. of West Bengal.

Research Focus

Assist. Prof. Dr. Saikat Chaudhuri is a rising expert in synthetic organic chemistry and medicinal chemistry. His research focuses on the development of novel synthetic methodologies 🧪 for constructing complex heterocycles, such as indoles, benzazepinoindoles, and spiro compounds 🌱. These molecules show promising biological activity, including antibacterial and antifungal properties 💊🦠. He also explores green chemistry approaches, metal-free catalysis, and the total synthesis of natural products 🌍. His work significantly contributes to drug discovery and design, making him a valuable contributor to pharmaceutical research and sustainable chemistry.

Publication Top Notes

Synthesis of Dihydro‐benzazepinoindoles via an Oxidative Pictet–Spengler Reaction

A New Homogeneous Catalyst for the Synthesis of 3,3′‐Bis(indolyl)methanes: Collective Synthesis of Arundine, Turbomycin B, Arsindoline A, and Tris(1H‐Indol‐3‐yl)methane*

A Transition Metal‐Free Strategy for Dihydrobenzazepinoindole via KI‐Mediated Oxidative Pictet–Spengler Reaction

Pentafluorophenol‐Catalyzed Metal‐Free Fischer Indole Synthesis: A Novel Approach to Carbazole Derivatives and Desbromoarborescidine A*

Water Mediated Chemoselective Synthesis of Novel Spiro Benzoxazinoindoline and Extended Synthesis of Spiro Benzoxazinoindene Derivatives*

A Practical and Metal‐Free Approach Towards Synthesis of Spiro‐Benzazepinoindole Derivatives via Pentafluorophenol Catalyzed Pictet‐Spengler Reaction**

Efficient, One‐Pot, Green Syntheses of Analogues of 3,4‐Dihydro‐2H Pyrroles as Potential New Antifungal and Antibacterial Agents.

A convenient proline catalysed Paal–Knorr synthesis of highly substituted pyrrole: construction of a pyrrolo[2,1-a]isoquinoline scaffold

Syntheses of Novel Spirobenzazepinoindole Derivatives via Lewis‐Acid Catalyzed Pictet‐Spengler Cyclization

Self-Healable Hydrogels from Vegetable Oil: Preparation, Mechanism, and Applications

A Comprehensive Review of Synthetic Approaches Toward Lamellarin D and its Analogous

Catalytic Asymmetric Approach to the Naturally Occurring Clavine Alkaloid, (+)-Lysergine

Harnessing leather waste in polymer matrix for sustainable smart <scp>shape‐stable</scp> phase change materials

Green synthetic approaches for medium ring-sized heterocycles of biological and pharmaceutical interest

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Published on 08/07/202508/07/2025 by Top Pharmaceutical

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Prof. lingcong KONG at Jilin Agriculture University, China.

Prof. Lingcong Kong is a dedicated veterinary scientist with a Ph.D. in Preventive Veterinary Medicine from Jilin Agricultural University 🎓. He teaches courses like Veterinary Pharmacology and Animal Toxicology 🐄 and actively mentors students in national competitions 🏆. His research focuses on antimicrobial resistance, drug resistance mechanisms, and the development of resistance inhibitors in animal pathogens 🧫🦠. He has led numerous national and provincial projects, holds multiple patents for veterinary vaccines 💉, and has published extensively in high-impact journals 📚. His work significantly enhances diagnostic tools and contributes to sustainable animal healthcare.

Publication Profile

Scopus

Education

Prof. Lingcong Kong began his academic journey at the Inner Mongolia University for Nationalities, where he earned his Bachelor of Veterinary Medicine from September 2006 to July 2010 🐾. He then pursued advanced studies at Jilin Agricultural University, completing a Master’s degree in Basic Veterinary Medicine between 2010 and 2013 🧪. Driven by a deep passion for animal health, he continued at the same institution to earn his Ph.D. in Preventive Veterinary Medicine from September 2013 to July 2016 🔬. His education laid a strong foundation for his impactful contributions to veterinary science and research.

Experience

Prof. Lingcong Kong is a dedicated educator who teaches undergraduate courses such as “Veterinary Pharmacology”, “Veterinary Pharmacology Experiment”, and “Animal Toxicology” 🐾. At the graduate level, he lectures on “Veterinary Drug Research and Creation”, “Advanced Pharmacology”, and “Veterinary Pharmacology and Toxicology” 💊. He actively mentors students in scientific competitions, leading them to prestigious honors like the 2022 Internet+ National Award (2nd Prize) 🏅, Provincial Award (1st Prize) 🥇, and innovation contests. His guidance also earned him the Outstanding Paper Award 📝 and the Dazenong Innovation Guidance Award in 2018 🎖️, highlighting his commitment to academic excellence and innovation.

Awards

Prof. Lingcong Kong has pioneered breakthroughs in detecting and combating drug-resistant animal pathogens 🐄🧫. His innovations include PCR-ELISA rapid detection, immunomagnetic bead enrichment, and high-throughput methods for resistance gene testing 🧪. He established a pathogenic bacteria resource library 📚 and developed functional probiotics to prevent animal diarrhea 💊. By identifying 8 key resistance inhibitor targets and 6 promising lead compounds, his work has revolutionized lab diagnostics, minimized economic losses in livestock, and enhanced ecological health 🌱💼. His efforts significantly advance animal healthcare and veterinary pharmacology across Jilin Province and beyond.

Research Focus

Prof. Lingcong Kong focuses on veterinary pharmacology, particularly targeting antimicrobial resistance and infectious diseases in animals 🐄🦠. His cutting-edge research includes discovering novel natural inhibitors like coniferaldehyde and protocatechuic aldehyde to combat Staphylococcus aureus 🧪🔬. He also explores gene transfer mechanisms, antibiotic degradation pathways, and repurposing small molecules to inhibit bacterial enzymes like KPC-2 💊. By studying agents such as C15-bacillomycin D and antibacterial proteins from Bacillus velezensis, he contributes significantly to combatting multidrug-resistant pathogens in animal and environmental health.

Publication Top Notes

Discovery of coniferaldehyde as an inhibitor of caseinolytic protease to combat Staphylococcus aureus infections

Anti-infective therapy of inhibiting Staphylococcus aureus ClpP by protocatechuic aldehyde

Acidifiers promoted antibiotic resistance gene transfer via plasmid conjugation

Efficient degradation of tylosin by Kurthia gibsonii TYL-A1: performance, pathway, and genomics study

Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption

A Novel Protein Demonstrating Antibacterial Activity Against Multidrug-Resistant Escherichia coli Purified from Bacillus velezensis CB6

C15-bacillomycin D produced by Bacillus amyloliquefaciens 4-9-2 suppress Fusarium graminearum infection and mycotoxin biosynthesis

Qun Tang | Drug Discovery and Development | Best Researcher Award

Published on 02/07/202502/07/2025 by Top Pharmaceutical

Qun Tang | Drug Discovery and Development | Best Researcher Award

Dr. Qun Tang, Nanchang university, China

Dr. Qun Tang earned his Ph.D. in Chemistry from USTC in 2005. Following postdoctoral research in South Korea and Sweden, he launched his independent lab at Nanchang University in 2010. His research focuses on Mn-based contrast agents 🧲, arsenic-derived anticancer drugs 💊, and innovative treatments for liver diseases using low phosphate stress (LPS) approaches 🧬. With 46 SCI papers, 1,489 citations 📚, and 3 authorized patents, Dr. Tang is a key contributor to pharmaceutical sciences. He is a Standing Committee Member of Jiangxi Pharmaceutical Society and collaborates with leading researchers to advance drug development globally.

Publication Profile

Scopus

Education

Dr. Qun Tang earned his Ph.D. in January 2005 from the University of Science and Technology of China (USTC) 🎓. After postdoctoral collaborations in South Korea and Sweden 🌍, he returned to Nanchang University in March 2010 to begin his independent research career 🔬. His work has focused on manganese (Mn)-based materials for medical imaging contrast agents 🧲 and the development of novel arsenic-based anticancer drugs 💊. Currently, Dr. Tang is pioneering research on low phosphate (Pi) stress (LPS)-based strategies for the prevention and treatment of diseases, particularly targeting liver-related conditions 🧬. His contributions continue to shape pharmaceutical innovation globally.

Professional Memberships

Dr. Qun Tang holds a distinguished position as a Standing Committee Member of the Jiangxi Provincial Pharmaceutical Society 🏛️. This prestigious role reflects his commitment to advancing pharmaceutical sciences within the region and contributing to public health initiatives at the provincial level 📈. Through this membership, Dr. Tang actively engages in scientific discourse, policy guidance, and collaborative research opportunities with fellow experts across Jiangxi and beyond 🤝. His leadership within the society underscores his dedication to professional excellence and innovation in drug development and pharmaceutical research 💊🔬. This role further enhances his influence within China’s scientific and medical communities.

Research Focus

Dr. Qun Tang’s research squarely targets phosphate‑modulated liver oncology and theranostics 🧬🩺. He engineers inorganic‑phosphate binders and polymeric drug‑loading beads 🟤 to perform trans‑arterial embolization, simultaneously starving tumors and reshaping the micro‑environment 🎯. By blocking XPR1‑mediated phosphate efflux, his team triggers mitochondrial dysfunction in hepatocellular carcinoma cells ⚡️, while low‑Pi stress irreversibly repolarizes tumor‑associated macrophages 🛡️ and dampens angiogenesis 🌱. Tang also discovers how binders like sevelamer deactivate hepatic stellate cells to reverse fibrosis 🧫. Overall, his work fuses immunometabolism, interventional radiology, and targeted drug delivery to forge next‑gen therapies for liver cancer and chronic liver disease.

Publication Top Notes

Transarterial Embolization Using an Inorganic Phosphate Binder Modulates Immunity- and Angiogenesis-Related Factors in a Rat Model of Liver Cancer

Design and progress of drug-loading polymeric bead for tumor embolization

Inhibition of XPR1-dependent phosphate efflux induces mitochondrial dysfunction: A potential molecular target therapy for hepatocellular carcinoma?

Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells

Irreversible repolarization of tumour-associated macrophages by low-Pi stress inhibits the progression of hepatocellular carcinoma

José Leite | Drug Discovery and Development | Innovator in Pharmaceutical Research Award

Published on 24/06/202524/06/2025 by Top Pharmaceutical

José Leite | Drug Discovery and Development | Innovator in Pharmaceutical Research Award

Dr. José Leite, Universidade de Brasília – UnB, Brazil

Dr. José Roberto Leite is a Brazilian biochemist and molecular biologist with a PhD from the University of Brasília 🇧🇷 and postdoctoral training at EMBRAPA and the University of Porto 🇵🇹. He is an Associate Professor at UnB’s Faculty of Medicine and Visiting Researcher at i3S. 🧪 As co-founder of People&Science, he works on biotechnology, nanobiotech, and bioactive peptides for health and environment 🌿. With 200+ international publications 📚, patents under development 💡, and global collaborations 🌍, he bridges biodiversity and innovation. Dr. Leite also serves as Associate Editor of the Journal of Global Innovation.

Publication Profile

Google Scholar

Education

Dr. José Roberto Leite earned his PhD in Biological Sciences (Biochemistry/Molecular Biology) from the University of Brasília 🇧🇷 and completed postdoctoral training at EMBRAPA and the University of Porto (REQUIMTE) 🇵🇹. He serves as an Associate Professor at UnB’s Faculty of Medicine and is a Visiting Researcher at i3S 🧬. He coordinated graduate programs at UFPI and UnB and founded the Biotec/UFPI research group 🧑‍🔬. As co-founder of People&Science, he leads cutting-edge work in biotechnology, nanobiotechnology, and bioprospecting for health and the environment 🌱. He is also Associate Editor of the Journal of Global Innovation 📘 and promotes international collaboration.

Professional Memberships

Dr. José Roberto Leite is actively engaged in Brazil’s leading scientific communities and holds esteemed memberships in the Brazilian Society for Biochemistry and Molecular Biology 🧪 and the Brazilian Society of Biotechnology 🧬, reflecting his deep commitment to advancing life sciences and innovation. In addition, he plays a key editorial role 📖 in the Journal of Global Innovation (JGI), contributing to the dissemination of cutting-edge research and fostering interdisciplinary collaboration 🌐. His involvement in these professional circles underscores his dedication to scientific excellence, knowledge sharing, and the promotion of impactful biotechnology and molecular biology initiatives across Brazil and beyond.

Research Focus

Dr. José Roberto Leite focuses on cutting-edge research in biotechnology, nanobiotechnology, and natural product-based drug discovery 🌱. His work spans the development of bioactive peptides 🧬, antimicrobial and anticancer compounds 💊, and innovative drug delivery systems 🚀. He explores biodiversity to identify novel molecules from amphibians 🐸, plants 🌿, and marine life 🌊 for therapeutic and diagnostic applications. Dr. Leite also contributes to the advancement of biosensors, nutraceuticals, and functional biomaterials. His interdisciplinary research bridges biochemistry, molecular biology, and pharmacology, driving translational science for global health and environmental impact.